Gowen Benjamin G, Chim Bryan, Marceau Caleb D, Greene Trever T, Burr Patrick, Gonzalez Jeanmarie R, Hesser Charles R, Dietzen Peter A, Russell Teal, Iannello Alexandre, Coscoy Laurent, Sentman Charles L, Carette Jan E, Muljo Stefan A, Raulet David H
Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California, Berkeley, Berkeley, United States.
Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, Bethesda, United States.
Elife. 2015 Nov 13;4:e08474. doi: 10.7554/eLife.08474.
Recognition and elimination of tumor cells by the immune system is crucial for limiting tumor growth. Natural killer (NK) cells become activated when the receptor NKG2D is engaged by ligands that are frequently upregulated in primary tumors and on cancer cell lines. However, the molecular mechanisms driving NKG2D ligand expression on tumor cells are not well defined. Using a forward genetic screen in a tumor-derived human cell line, we identified several novel factors supporting expression of the NKG2D ligand ULBP1. Our results show stepwise contributions of independent pathways working at multiple stages of ULBP1 biogenesis. Deeper investigation of selected hits from the screen showed that the transcription factor ATF4 drives ULBP1 gene expression in cancer cell lines, while the RNA-binding protein RBM4 supports ULBP1 expression by suppressing a novel alternatively spliced isoform of ULBP1 mRNA. These findings offer insight into the stress pathways that alert the immune system to danger.
免疫系统对肿瘤细胞的识别和清除对于限制肿瘤生长至关重要。当受体NKG2D与原发性肿瘤和癌细胞系中频繁上调的配体结合时,自然杀伤(NK)细胞被激活。然而,驱动肿瘤细胞上NKG2D配体表达的分子机制尚未明确。通过在肿瘤来源的人类细胞系中进行正向遗传筛选,我们鉴定出了几个支持NKG2D配体ULBP1表达的新因子。我们的结果显示了在ULBP1生物合成的多个阶段起作用的独立途径的逐步贡献。对筛选中选定的命中靶点进行更深入的研究表明,转录因子ATF4驱动癌细胞系中ULBP1基因的表达,而RNA结合蛋白RBM4通过抑制ULBP1 mRNA的一种新的可变剪接异构体来支持ULBP1的表达。这些发现为提醒免疫系统注意危险的应激途径提供了见解。